P. Pieslor

Ultrastructure of myofibroblasts and decidualized cells in leiomyomatosis peritonealis disseminata.

J. Orenstein, D. Hogan, A. Breslow, 1979, American journal of clinical pathology.

Barriers to achieving commercial success for diagnostic and therapeutic radiopharmaceuticals.

P. Pieslor, 2007, Nuclear medicine and biology.

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

M. von Mehren, Z. Wainberg, C. Britten, 2014, Investigational New Drugs.

The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.

P. Conti, P. Foster, C. White, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.

L. Gordon, M. Czuczman, S. Ansell, 2004, Clinical lymphoma.

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

T. Bush, A. Coxon, R. Radinsky, 2013 .

Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM

E. D. de Vries, J. Kosterink, M. Friedrich, 2016, The Journal of Nuclear Medicine.

Umbilical metastasis from prostatic carcinoma--Sister Joseph nodule.

P. Pieslor, L. Hefter, 1986, Urology.

Three radioligands compared for determining cytoplasmic estrogen-receptor content of human breast carcinomas.

R. Reba, W. Eckelman, R. Gibson, 1982, Clinical chemistry.